PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced today the appointment of Jay E. Birnbaum, Ph.D., to its board of directors. Dr. Birnbaum is a pharmacologist and previous to his current role as a consultant to pharmaceutical companies, he served as vice president of global project management at Novartis/Sandoz Pharmaceuticals Corporation, where he had responsibility for strategic planning and development of the company’s dermatology portfolio. In this position, he directed clinical programs and NDA submissions on products including terbinafine (Lamisil®) and cyclosporine (Neoral/Sandimmune®). He headed a number of corporate initiatives dealing with the standardization and quality of clinical trials and was chairman of Organogenesis/Novartis joint development committee during the development and registration of Apilgraf®.
